GT-02287 Clinical & Preclinical Data at AD/PD 2026

Gain Therapeutics, Inc. announced the presentation of data from its Phase 1b clinical study of GT-02287 and preclinical data from a new series of GCase modulators at the AD/PD™ 2026 conference. The oral presentation highlighted new clinical and biomarker data supporting GT-02287's disease-modifying potential in Parkinson's disease. Key findings included sustained stability in MDS-UPDRS scores over 150 days of treatment and a decrease in DOPA decarboxylase (DDC) levels in participants with high baseline glucosylsphingosine (GluSph). The poster presentation showcased preclinical data from a novel chemical series, led by GT-04686, which are ready for IND-enabling studies for Parkinson's disease and other neurological disorders. The company reported that GT-02287 is well-tolerated, demonstrating target engagement and supporting its potential for both idiopathic and GBA1 Parkinson's disease.